Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Oprelvekin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Oprelvekin: Patents, clinical trial progress, indications

Oprelvekin is an investigational drug.

There have been 4 clinical trials for Oprelvekin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2008.

The most common disease conditions in clinical trials are Von Willebrand Diseases, Thrombocytopenia, and Leukemia, Myeloid. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, University of North Carolina, and University of Pittsburgh.

Recent Clinical Trials for Oprelvekin
Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced ThrombocytopeniaPfizerPhase 2
IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryUniversity of North CarolinaPhase 2
IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryWyeth is now a wholly owned subsidiary of PfizerPhase 2

See all Oprelvekin clinical trials

Clinical Trial Summary for Oprelvekin

Top disease conditions for Oprelvekin
Top clinical trial sponsors for Oprelvekin

See all Oprelvekin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.